Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | USP2 | O75604 | 3/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683274 | 0.94 | TSHR (0.33) | TSHRTDP1ALDH1A1USP2CYP3A4 | |
| SCHEMBL14301167 | 0.94 | USP2 (0.34) | TSHRTDP1ALDH1A1USP2CYP3A4 | |
| SCHEMBL18685052 | 0.89 | USP2 (0.33) | TSHRTDP1ALDH1A1USP2CYP3A4 | |
| SCHEMBL15013678 | 0.89 | THRB (0.43) | TSHRTDP1ALDH1A1USP2CYP3A4 | |
| SCHEMBL15870392 | 0.87 | THRB (0.42) | TDP1ALDH1A1USP2CYP3A4MAPT | |
| SCHEMBL16568192 | 0.87 | THRB (0.42) | TDP1USP2CYP3A4SMN1; SMN2 | |
| SCHEMBL2787443 | 0.87 | TSHR (0.41) | TSHRTDP1ALDH1A1MAPK1LMNA | |
| SCHEMBL428260 | 0.86 | GPR84 (0.40) | TSHRALDH1A1MAPTGPR84 | |
| SCHEMBL15484241 | 0.86 | TDP1 (0.38) | TSHRTDP1ALDH1A1USP2CYP3A4 | |
| SCHEMBL17340654 | 0.85 | TSHR (0.39) | TSHRALDH1A1USP2CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251289-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CANCER | CSIR (ZA) | 2011-10-13 | — | — | US | disclosed |
| EP-2321259-A2 | NEW COMPOUNDS FOR THE TREATMENT OF CANCER | CSIR (ZA) | 2011-05-18 | — | — | EP | disclosed |
| WO-2009147632-A2 | NEW COMPOUNDS FOR THE TREATMENT OF CANCER | CSIR (ZA) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251289-A1 | NEW COMPOUNDS FOR THE TREATMENT OF CANCER | DUT, BAD, TYMS | TSHR 2050/4885TDP1 965/4885ALDH1A1 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.